ALSUntangled No. 7: Investigating hyperimmune goat serum (Aimspro) for ALS.
Document Type
Article
Abstract
The mechanism of Aimspro remains unproven; if it is an immunomodulator and/or a modulator of sodium channels, it theoretically could be useful in ALS. A single, detailed but significantly flawed case report documents slowing in decline of certain respiratory functions in a patient claiming to have ALS, who started Aimspro shortly after bipap. Based upon this limited information, ALSUntangled supports further study of Aimspro, either in ALS animal models or in a small phase 2 trial with clear and objective endpoints carried out by skilled trialists familiar with the problems inherent with ALS clinical studies. Until a trial is undertaken, however, we do not support further use of this product by PALS.
Keywords
Amyotrophic Lateral Sclerosis, Animals, Clinical Trials as Topic, Goats, Humans, Internet, Serum
Medical Subject Headings
Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Goats; Humans; Internet; Serum
Publication Date
12-1-2010
Publication Title
Amyotroph Lateral Scler
ISSN
1471-180X
Volume
11
Issue
6
First Page
571
Last Page
573
PubMed ID
21077806
Recommended Citation
Bowser, Robert and ALSUntangled Group, "ALSUntangled No. 7: Investigating hyperimmune goat serum (Aimspro) for ALS." (2010). Translational Neuroscience. 1112.
https://scholar.barrowneuro.org/neurobiology/1112